No data available.
Please log in to see this content.
You have no subscription access to this content.
No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.
Potential third-party radiation exposure from outpatients treated with for hyperthyroidism
1.D. S. Ross, E. C. Ridgway, and G. H. Daniels, “Successful treatment of solitary toxic thyroid nodules with relatively low-effective dose iodine-131, with low prevalence of hypothyroidism,” Ann. Intern Med. 101, 488–490 (1984).
2.L. Hegedus, D. Veiergang, S. Karstrup, and J. M. Hansen, “Compensated therapy of solitary autonomous thyroid nodules: Effect on thyroid size and early hypothyroidism,” Acta Endocrinol. 113, 226–232 (1986).
3.D. A. Huysmans, F. H. Corstens, and P. W. Kloppenborg, “Long-term follow-up in toxic solitary autonomous thyroid nodules treated with radioactive iodine,” J. Nucl. Med. 32, 27–30 (1991).
4.C. Reiners and P. Shneider, “Radioiodine therapy of thyroid autonomy,” Eur. J. Nucl. Med. 29(Suppl. 2), S471–478 (2002).
5.M. J. Reinhardt, A. Joe, D. von Mallek, M. Zimmerlin, A. M. Manka-Waluch, H. Palmedo, and T. M. Krause, “Effective dose selection for radioiodine therapy of borderline hyperthyroid patients with multifocal and disseminated autonomy on the basis of -pertechnetate thyroid uptake,” Eur. J. Nucl. Med. 29, 480–485 (2002).
6.R. C. T. Buchan and J. M. Brindle, ”Radioiodine therapy to out-patients—the contamination hazard,” Br. J. Radiol. 43, 479–482 (1970).
7.K. Nishizawa, K. Ohara, M. Oshima, H. Maekoshi, T. Orito, and T. Wanatabe, “Monitoring of I excretions and used materials of patients treated with ,” Health Phys. 76, 129–136 (1999).
8.E. Ibis, C. R. Wilson, D. Collier, G. Akansel, A. T. Isitman, and R. G. Yoss, “Iodine-131 contamination from thyroid cancer patients,” J. Nucl. Med. 33, 2110–2115 (1992).
9.M. J. O’Doherty, A. G. Kettle, C. N. P. Eustance, P. J. Mountford, and A. J. Coakley, “Radiation effective dose rates from adult patients receiving therapy for thyrotoxicosis,” Nucl. Med. Commun. 14, 160–168 (1993).
10.M. Monsieur, H. Thierens, R. A. Dierckx, K. Casier, E. De Baere, L. De Ridder, C. De Saedeleer, H. De Winter, M. Lippens, S. van Imschoot, D. Wulfrank, and M. Simons, “Real life radiation burden to relatives of patients treated with iodine-131: A study in eight centres in Flanders (Belgium),” Eur. J. Nucl. Med. 25, 1368–1376 (1998).
11.S. F. Barrington, M. J. O’Doherty, A. G. Kettle, W. H. Thomson, P. J. Mountford, D. N. Burrell, R. J. Farrell, S. Batchelor, P. Seed, and L. K. Harding, “Radiation exposure of the families of outpatients treated with radioiodine (iodine-131) for hyperthyroidism,” Eur. J. Nucl. Med. 26, 686–692 (1999).
12.I. Mathieu, J. Caussin, P. Smeester, P. A. Wambersie, and C. Beckers, “Recommended restrictions after therapy: Measured effective doses in family members,” Health Phys. 76, 129–136 (1999).
13.Council of the European Union. Directive on the Health Protection of Individuals against the dangers of ionizing radiation in relation to medical exposure, 97/43/Euratom OJ L180, 22–27 (1997).
14.European Commission. Radiation Protection 97. Radiation protection following Iodine-131 therapy (exposures due to out-patients or discharged in-patients). Luxembourg, Office for Official Publications of the European Communities, 1998.
15.C. Beckers, “Regulations and policies on radioiodine therapy in Europe,” Thyroid 7, 221–224 (1997).
16.C. M. Culver and H. J. Dworkin, “Radiation safety considerations for post-iodine-131 thyroid cancer therapy,” J. Nucl. Med. 33, 1402–1405 (1992).
17.E. Reschini, R. Matheoud, C. Canzi, M. Castellani, M. Galelli, C. Ferrari, A. Paracchi, and P. Gerundini, “Dosimetry study in patients with autonomous thyroid nodule who are candidates for radioiodine therapy,” J. Nucl. Med. 40, 1928–1934 (1999).
18.R. Matheoud, C. Canzi, E. Reschini, F. Zito, F. Voltini, and P. Gerundini, “Tissue-specific dosimetry for radioiodine therapy of the autonomous thyroid nodule,” Med. Phys. 30, 791–798 (2003).
19.A. Bockish, T. Jamitzky, R. Derwanz, and H. J. Biersack, “Optimized effective dose planning of radioiodine therapy of benign thyroidal diseases,” J. Nucl. Med. 34, 1632–1638 (1993).
20.J. A. Siegel, C. S. Marcus, and R. B. Sparks, ”Calculating the absorbed effective dose from radioactive patients: The line source versus point-source model,” J. Nucl. Med. 43, 1241–1244 (2002).
21.A. D. Wrixon, G. S. Linsley, K. C. Binns, and D. F. White, “Derived limits for surface contamination,” NRPB-DL2, November 1979, Harwell, Didcot, Oxon, OX11 ORQ.
22.International Commission on Radiation Protection n.60, Recommendations of the International Commission on Radiological Protection, Vol. 21, No. 1–3 (Pergamon, Oxford, 1992).
23.P. B. Zanzonico, J. A. Siegel, and J. St. Germain, “A generalized algorithm for determining the time of release and the duration of post-release radiation precautions following radionuclide therapy,” Health Phys. 78, 648–659 (2000).
24.National Council on Radiation Protection and Measurements Commentary n.11, “Effective dose limits for individuals who receive exposure from radionuclide therapy patients,” Bethesda, MD, 1995.
25.International Commission on Radiation Protection n.68, Effective Dose Coefficients for Intakes of Radionuclides by Workers, Vol. 24, No. 4 (Pergamon, Oxford, 1994).
Article metrics loading...
Full text loading...
Most read this month